151 related articles for article (PubMed ID: 33067653)
1. Application of target repositioning and in silico screening to exploit fatty acid binding proteins (FABPs) from Echinococcus multilocularis as possible drug targets.
Bélgamo JA; Alberca LN; Pórfido JL; Romero FNC; Rodriguez S; Talevi A; Córsico B; Franchini GR
J Comput Aided Mol Des; 2020 Dec; 34(12):1275-1288. PubMed ID: 33067653
[TBL] [Abstract][Full Text] [Related]
2. Fatty acid-binding proteins in Echinococcus spp.: the family has grown.
Pórfido JL; Herz M; Kiss F; Kamenetzky L; Brehm K; Rosenzvit MC; Córsico B; Franchini GR
Parasitol Res; 2020 Apr; 119(4):1401-1408. PubMed ID: 32130486
[TBL] [Abstract][Full Text] [Related]
3. On the importance of targeting parasite stem cells in anti-echinococcosis drug development.
Brehm K; Koziol U
Parasite; 2014; 21():72. PubMed ID: 25526547
[TBL] [Abstract][Full Text] [Related]
4. Anti-echinococcal effect of verapamil involving the regulation of the calcium/calmodulin-dependent protein kinase II response in vitro and in a murine infection model.
Gao HJ; Sun XD; Luo YP; Pang HS; Ma XM; Zhang T; Jing T; Hu W; Shen YJ; Cao JP
Parasit Vectors; 2021 Feb; 14(1):108. PubMed ID: 33588933
[TBL] [Abstract][Full Text] [Related]
5. Repurposing of an old drug: In vitro and in vivo efficacies of buparvaquone against Echinococcus multilocularis.
Rufener R; Dick L; D'Ascoli L; Ritler D; Hizem A; Wells TNC; Hemphill A; Lundström-Stadelmann B
Int J Parasitol Drugs Drug Resist; 2018 Dec; 8(3):440-450. PubMed ID: 30396011
[TBL] [Abstract][Full Text] [Related]
6. Treatment of echinococcosis: albendazole and mebendazole--what else?
Hemphill A; Stadelmann B; Rufener R; Spiliotis M; Boubaker G; Müller J; Müller N; Gorgas D; Gottstein B
Parasite; 2014; 21():70. PubMed ID: 25526545
[TBL] [Abstract][Full Text] [Related]
7. Progress in the pharmacological treatment of human cystic and alveolar echinococcosis: Compounds and therapeutic targets.
Siles-Lucas M; Casulli A; Cirilli R; Carmena D
PLoS Negl Trop Dis; 2018 Apr; 12(4):e0006422. PubMed ID: 29677189
[TBL] [Abstract][Full Text] [Related]
8. Drug repurposing applied: Activity of the anti-malarial mefloquine against Echinococcus multilocularis.
Lundström-Stadelmann B; Rufener R; Hemphill A
Int J Parasitol Drugs Drug Resist; 2020 Aug; 13():121-129. PubMed ID: 32636148
[TBL] [Abstract][Full Text] [Related]
9. In Vitro and in Vivo Effect of MAPK Signal Transduction Pathway Inhibitors on Echinococcus multilocularis.
Gui WF; Xu S; Dang ZS; Zhao YM
J Parasitol; 2019 Feb; 105(1):146-154. PubMed ID: 30807708
[TBL] [Abstract][Full Text] [Related]
10. Oral treatments of Echinococcus multilocularis-infected mice with the antimalarial drug mefloquine that potentially interacts with parasite ferritin and cystatin.
Küster T; Stadelmann B; Rufener R; Risch C; Müller J; Hemphill A
Int J Antimicrob Agents; 2015 Nov; 46(5):546-51. PubMed ID: 26395219
[TBL] [Abstract][Full Text] [Related]
11. In vitro efficacy of ampelopsin against Echinococcus granulosus and Echinococcus multilocularis.
Xin Q; Yuan M; Li H; Lu J; Song X; Jing T
J Vet Med Sci; 2019 Dec; 81(12):1853-1858. PubMed ID: 31748438
[TBL] [Abstract][Full Text] [Related]
12. Genetic diversity of Echinococcus multilocularis and Echinococcus granulosus sensu lato in Kyrgyzstan: The A2 haplotype of E. multilocularis is the predominant variant infecting humans.
Alvarez Rojas CA; Kronenberg PA; Aitbaev S; Omorov RA; Abdykerimov KK; Paternoster G; Müllhaupt B; Torgerson P; Deplazes P
PLoS Negl Trop Dis; 2020 May; 14(5):e0008242. PubMed ID: 32401754
[TBL] [Abstract][Full Text] [Related]
13. In vitro efficacy of the anticancer drug imatinib on Echinococcus multilocularis larvae.
Hemer S; Brehm K
Int J Antimicrob Agents; 2012 Nov; 40(5):458-62. PubMed ID: 22947125
[TBL] [Abstract][Full Text] [Related]
14. Expression profiling of Echinococcus multilocularis miRNAs throughout metacestode development in vitro.
Macchiaroli N; Preza M; Pérez MG; Kamenetzky L; Cucher M; Koziol U; Castillo E; Berriman M; Brehm K; Rosenzvit MC
PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009297. PubMed ID: 33750964
[TBL] [Abstract][Full Text] [Related]
15. Screening of the Open Source Malaria Box Reveals an Early Lead Compound for the Treatment of Alveolar Echinococcosis.
Stadelmann B; Rufener R; Aeschbacher D; Spiliotis M; Gottstein B; Hemphill A
PLoS Negl Trop Dis; 2016 Mar; 10(3):e0004535. PubMed ID: 26967740
[TBL] [Abstract][Full Text] [Related]
16. Innovative chemotherapeutical treatment options for alveolar and cystic echinococcosis.
Hemphill A; Spicher M; Stadelmann B; Mueller J; Naguleswaran A; Gottstein B; Walker M
Parasitology; 2007 Nov; 134(Pt 12):1657-70. PubMed ID: 17631693
[TBL] [Abstract][Full Text] [Related]
17. Molecular characteristics of Echinococcus multilocularis FABP1 and its regulatory functions on murine macrophages.
Li X; Liao P; Zhou W; Yang X; Ye B
Acta Trop; 2024 Jul; 255():107247. PubMed ID: 38729330
[TBL] [Abstract][Full Text] [Related]
18. Drug repurposing for the treatment of alveolar echinococcosis:
Fabbri J; Pensel PE; Albani CM; Arce VB; Mártire DO; Elissondo MC
Parasitology; 2019 Nov; 146(13):1620-1630. PubMed ID: 31397256
[TBL] [Abstract][Full Text] [Related]
19. Echinococcus metacestodes as laboratory models for the screening of drugs against cestodes and trematodes.
Hemphill A; Stadelmann B; Scholl S; Müller J; Spiliotis M; Müller N; Gottstein B; Siles-Lucas M
Parasitology; 2010 Mar; 137(3):569-87. PubMed ID: 19765346
[TBL] [Abstract][Full Text] [Related]
20. Activity of mefloquine and mefloquine derivatives against Echinococcus multilocularis.
Rufener R; Ritler D; Zielinski J; Dick L; da Silva ET; da Silva Araujo A; Joekel DE; Czock D; Goepfert C; Moraes AM; de Souza MVN; Müller J; Mevissen M; Hemphill A; Lundström-Stadelmann B
Int J Parasitol Drugs Drug Resist; 2018 Aug; 8(2):331-340. PubMed ID: 29933218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
